Journey Medical Corporation ( (DERM) ) has released its Q2 earnings. Here is a breakdown of the information Journey Medical Corporation presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Journey Medical Corporation is a commercial-stage pharmaceutical company specializing in the marketing of FDA-approved prescription products for dermatological conditions, based in Scottsdale, Arizona. The company recently announced its financial results for the first quarter of 2025, highlighting a strong start to the commercial launch of Emrosi™, an oral treatment for rosacea.
In the first quarter of 2025, Journey Medical reported revenues of $13.1 million, consistent with the previous year’s first quarter. The launch of Emrosi™ contributed $2.1 million to this revenue. The company also improved its gross margin to 64% from 54% in the prior year, attributed to a favorable product sales mix and reduced costs. Additionally, the net loss decreased significantly to $4.1 million from $10.4 million in the same period last year.
Strategically, Journey Medical has made significant strides with Emrosi™, which has been well-received in the dermatology community. The product’s Phase 3 clinical trial results were published in JAMA Dermatology, demonstrating its superiority over existing treatments. Emrosi™ has also been included in the National Rosacea Society’s updated treatment algorithms, and its payer coverage is expanding.
Looking ahead, Journey Medical’s management remains optimistic about the company’s trajectory, emphasizing their strong cash position and the potential for 2025 to be a transformative year. The focus will be on achieving sustainable positive EBITDA and profitability through strategic execution and continued growth in their dermatology product portfolio.